TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04070781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles
Study: NCT02264275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
Study: NCT04617782

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donepezil TDS
Description: Transdermal Delivery System

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Donepezil TDS
Description: Transdermal Delivery System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Oral
Study: NCT00379847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan
Description: IV
Study: NCT03416088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beverage consumption
Description: The participants drink 300ml wine (alcohol concentration:12.5%)or 300ml coffee (caffeine concentration 72 mg), or water.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily reading
Description: Reading paper books, playing video games with mobile phones, or non-reading for 8 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body motion
Description: Exercise or body postural changes
Study: NCT01307319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP HFA
Description: BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP HFA
Description: BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal aerosol
Description: Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
Study: NCT03494868

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Drink
Description: 2 - 12 oz drinks
Study: NCT02413918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloperidone
Description: Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
Study: NCT03973216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A primary care group-based therapeutic yoga program
Description: The intervention includes therapeutic yoga training and education sessions on benefits of yoga and effects of stress on the body.
Study: NCT01476059

Intervention type: OTHER
Group type: OTHER
Intervention: Telephone follow-up
Description: Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
Study: NCT02724969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MILK or Text4Baby text message intervention
Description: MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MILK or Text4Baby text message intervention
Description: MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
Study: NCT03216421

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: Quality of Life questionnaires will be completed by each subject.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaires
Description: Quality of Life questionnaires will be completed by each subject.
Study: NCT03350373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Single administration of FYU-981 under Fasted and fed conditions in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981
Description: Single administration of FYU-981 under Fasted and fed conditions in the morning.
Study: NCT01476059

Intervention type: OTHER
Group type: OTHER
Intervention: No telephone follow-up
Description: Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
Study: NCT01868490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytokine induced killer cells
Description: at least 10\*9 CIK cells, IV on day 0, 14, 28
Study: NCT01722305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT03693703

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bi-parametric MRI
Description: Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: multi-parametric MRI
Description: T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration
Study: NCT04531501

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva and NPS test
Description: N/A Our study will not impact their path of care as they will be doing an NHS test which will determine their path of care at the NHS

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva and NPS test
Description: N/A Our study will not impact their path of care as they will be doing an NHS test which will determine their path of care at the NHS
Study: NCT02865837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.~Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.~Right after, a scanner is performed with urinary catheter declamping and emptied bladder.~Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.~Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared.
Study: NCT04288999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Description: Preoperative chemoradiotherapy (CRT) followed by Surgery plus Adjuvant chemotherapy~Preoperative CRT: capecitabine (1650 mg/m2/day) and radiotherapy (50.4 Gy/28 Fr)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure
Description: Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Procedure
Description: Surgery for Locally Recurrent Rectal Cancer (LRRC) will be performed within 42 days from registration for the patients in arm A, and between days 56 and 98 from the completion of the preCRT for the patients in arm B.~Appropriate surgical procedure will be performed to achieve R0 resection, such as low anterior resection, super low anterior resection, intersphincteric resection, Hartmann procedure, rectal amputation, pelvic exenteration, tumor resection, or lateral lymph node dissection
Study: NCT02000193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.~The treatment will continue until disease progression or intolerable AE.
Study: NCT04602273

Intervention type: DRUG
Intervention: Azacitidine Injection [Vidaza]
Study: NCT04388111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: 10mg of Morphine delivered Intraosseously
Study: NCT03189186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Same as arm description

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation uses liquid argon in metal needles to freeze tumors. Tumor cells are ruptured due to the forming ice crystals and die. Cryoablation is standardly used in tumors less then 4cm in diameter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrectomy
Description: Nephrectomy is the surgical excision of either the entire kidney or a small portion of the kidney. Nephrectomy is standardly used to treat renal cell cancer.
Study: NCT05200715

Intervention type: OTHER
Intervention: No intervention is foreseen by the protocol.
Description: Patients will be observed for 10 years at least. Demographic, genetic, clinical, clinimetric, laboratory, radiologic and therapeutic data will be collected both retrospectively and prospectively during routine follow-up visits.
Study: NCT01414894

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid manipulation
Description: Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid manipulation
Description: Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid manipulation
Description: Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid manipulation
Description: Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Manipulation
Description: Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Manipulation
Description: Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Manipulation
Description: Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure Manipulation
Description: Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
Study: NCT01105910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Ultra Lubricant Eye Drops
Description: 1 to 2 drops in each eye 4 times per day for 30 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensitive Eyes Eye Drops (Bausch & Lomb)
Description: 1 to 2 drops in each eye 4 times per day for 30 days
Study: NCT05301985

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preoperative nutrition
Description: The participants of experimental group consumed 400 ml of a clear carbohydrate drink (12,5 gr/100 ml carbohydrate, 50 kcal/100 ml, pH 5.0) at 10:00 pm the evening before surgery and 200 ml of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
Study: NCT04473209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal therapy
Description: supra and subgingival debridement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal therapy
Description: supra and subgingival debridement
Study: NCT00461617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitiglinide
Description: 10mg tablet, 10mg TID
Study: NCT03636659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B Liposome
Description: Manufactured for: Auromedics Pharma LLC, USA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AmBisome (Amphotericin B) Liposome
Description: Marketed by: Astellas Pharma US, Inc. USA
Study: NCT02823509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY 987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation-SR15-68_R84-089)
Study: NCT04428398

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of urine samples with flow cytometry
Description: Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of urine samples with flow cytometry
Description: Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326
Study: NCT02292108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dietetic counselling

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: dietetic counselling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis and self-hypnosis
Description: Erickson's hypnosis and self-hypnosis
Study: NCT06308822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT04497649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: daclatasuvir once daily
Study: NCT02454738

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultralow dose chest CT scan
Description: Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
Study: NCT01451723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT02533414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIRS with UAS
Description: Ureteral access sheath (UAS) will be used during RIRS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS without UAS
Description: Ureteral access sheath will not be used during RIRS.
Study: NCT01153165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
Study: NCT02932137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Patients receive low dose recombinant human Interleukin-2（HrIL-2）
Study: NCT03068871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACT
Description: Psycho-educational group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CET
Description: Psycho-educational group
Study: NCT00663364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiogel AI Lotion, Physiogel Lotion
Description: Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physiogel AI Lotion, Physiogel Lotion
Description: Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
Study: NCT01480960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation + whole body vibration training
Description: standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
Study: NCT04023526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine SC or IV will be administered at a standard dose of 75 mg/m\^2 on days 1-7 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine SC or IV will be administered at a standard dose of 75 mg/m\^2 on days 1-7 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cusatuzumab
Description: Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg on days 3 and 17 of each cycle.